Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Today Sponge

This article was originally published in The Tan Sheet

Executive Summary

FDA's NDAC to discuss remarketing and labeling of the vaginal contraceptive July 12 at the Holiday Inn in Bethesda, Md. Allendale Pharmaceuticals, which acquired the brand from American Home Products in December 1998, submitted a supplemental NDA (18-683) for the nonoxynol-9 contraceptive. The product was discontinued by AHP in 1995 due to manufacturing quality control shortcomings. In an April 24 citizen petition, D.C.-based Associated Pharmacologists & Toxicologists asked FDA to ban OTC sale of the sponge (1"The Tan Sheet" May 8, p. 9). An inspection of Allendale's manufacturing facility slated for May 22 was postponed by the agency, the company says. The July 12 meeting will run from 1 p.m. to 5:30 p.m.; parties interested in speaking during the open portion must file written submissions by July 6

You may also be interested in...



Allendale Pharma Today Sponge Relaunch $3 Mil. PR/Ad Campaign Planned

The U.S. relaunch of the Today Sponge is on the horizon, with an FDA inspection of the manufacturing facility for the OTC nonoxynol-9 contraceptive slated for the week of May 22. The product's marketer, Allendale Pharmaceuticals, submitted a supplemental NDA Jan. 23.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel